Core Viewpoint - The report from Citi indicates that China Biologic Products (01177) has underperformed expectations for revenue and profit in the second half of the 2025 fiscal year, with revenue growth of 10% year-on-year and a profit decline of 40% [1] Group 1: Financial Performance - Revenue for the second half of fiscal year 2025 is expected to grow by 10% year-on-year [1] - Profit is projected to decline by 40% year-on-year [1] Group 2: Future Outlook - Citi anticipates that the company will continue to launch new products and enhance sales of innovative products, which will be the main growth driver [1] - Revenue forecasts for the next two years have been revised down by 3% to 5%, and profit forecasts have been reduced by 11% to 13% [1] - The target price has been adjusted from HKD 9.2 to HKD 8.9, while maintaining an "outperform" rating [1] Group 3: Long-term Projections - Revenue growth rates for fiscal years 2026, 2027, and 2028 are projected to be 13%, 14%, and 12% respectively [1] - Net profit growth rates for fiscal years 2027 and 2028 are expected to be 15% and 13% respectively [1] - The launch of new innovative drugs and expansion of indications are expected to be the primary growth drivers [1]

Group 1 - The core viewpoint of the report is that China Biopharmaceutical (01177) is expected to achieve a 10.3% year-on-year growth in revenue from continuing operations in 2025, aligning with the company's previous guidance [1] - Revenue from innovative products is projected to grow by 26% year-on-year, contributing to 48% of total revenue [1] - The target price for China Biopharmaceutical has been adjusted down to HKD 7.7, while maintaining a "Buy" rating [1] Group 2 - The adjusted net profit of China Biopharmaceutical saw a significant increase of 31.4% last year [1] - New products expected to launch in 2026, including CDK2/4/6, Zongaitin, and KRAS, are anticipated to contribute significantly to performance growth [1] - The company is expected to maintain double-digit growth in product sales revenue from 2026 to 2027 [1]

茲提述中國生物製藥有限公司（「本公司」）日期為二零二六年一月十三日的公告（「該公告」），內容有關 收購赫吉亞100%股權（涉及根據一般授權發行代價股份）之股份交易。除另有界定者外，本公告所用 詞彙與該公告所定義者具有相同涵義。 完成收購事項 （於開曼群島註冊成立之有限公司） 網站：www.sbpgroup.com （股份編號：1177） 完成股份交易 收購赫吉亞100%股權 涉及根據一般授權發行代價股份 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 董事會欣然宣佈，買賣協議項下的所有先決條件均已獲達成且交割已於二零二六年三月三十日落 實。交割後，赫吉亞已成為本公司的間接全資附屬公司，且赫吉亞的財務業績將併入本集團的財務 報表。 有關收購事項的進一步資料 應付創始股東代價 誠如該公告所披露，創始股東應佔餘下50%基礎代價須以代價股份或股份之現金價值於二零二八年 四月二十九日及二零二九年四月二十九日分兩期支付。 1 此安排具有雙重目的： (1) 本公司 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 中國生物製藥有限公司 呈交日期： 2026年3月30日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01177 | 說明 | - | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關 ...

Core Viewpoint - Bank of America Securities reports that China's biopharmaceutical revenue reached 31.8 billion yuan in the previous year, reflecting a year-on-year growth of 10.3% [1] Group 1: Financial Performance - The sales revenue from innovative drugs amounted to 15.2 billion yuan, with a year-on-year increase of 26.2%, raising its share of total revenue from 41.8% in 2024 to 47.8% [1] - The profit attributable to shareholders was approximately 2.3 billion yuan, while the adjusted profit, excluding one-time gains and losses, was 4.5 billion yuan, representing a year-on-year growth of 31.4% [1] Group 2: Future Projections - Due to intensified competition, the bank has lowered revenue forecasts for several existing drugs but has included sales projections for newly approved products, expecting drug sales to grow by 10% to 11% annually from 2026 to 2028 [1] - Revenue forecasts for the same period have been adjusted downwards by 2.6%, 1.1%, and 1.3%, while gross margin forecasts have been increased by 0.3 to 0.6 percentage points to reflect efficiency improvements [1] Group 3: Investment Rating - The target price has been revised down from 8.9 HKD to 7.4 HKD, while maintaining a "Buy" rating [1]

Core Viewpoint - China Biopharmaceutical (01177) maintains a "Buy" rating, but the target price is lowered by 7.4% from HKD 9.4 to HKD 8.7, reflecting a downward adjustment in non-BD revenue expectations [1] Group 1: Financial Projections - The company is expected to achieve revenue growth of 13.5%/7.1%/9.2% for the years 2026/2027/2028, with non-BD revenue growth projected at 10.5%/10.0%/9.2% [1] - Adjusted net profit attributable to shareholders is forecasted to grow by 5.4%/8.3%/10.5% for the same years [1] Group 2: 2025 Financial Performance - In 2025, the company's revenue is projected to increase by 10.3% to RMB 31.83 billion, with innovative product revenue expected to rise by 26.2% to RMB 1.52 billion, accounting for 47.8% of total revenue (up from 37.8% in 2023) [1] - Adjusted net profit attributable to shareholders is anticipated to grow by 31.4% to RMB 4.54 billion, and even excluding dividends from Sinovac Biotech, the adjusted net profit is expected to increase by 15% [1] Group 3: Comparison with Market Expectations - The company's 2025 revenue is projected to be 7.4% lower than the firm's expectations and 3.9% lower than consensus estimates, while the adjusted net profit is expected to be 27.5% and 9% lower than the firm's and consensus estimates, respectively [1] - The shortfall is primarily due to the milestone payment of USD 300 million from Merck not being included in the 2025 revenue expectations [1] Group 4: Future Outlook - With stable revenue from generic drugs and continued growth in innovative drug sales, the company is expected to see steady performance in 2026 [1]

Investment Rating - The report maintains a "Buy" rating for China Biologic Products (1177 HK) [7] Core Views - The company reported a revenue growth of 10.3% year-on-year to RMB 31.83 billion for FY25, with innovative product revenue increasing by 26.2% to RMB 15.2 billion, accounting for 47.8% of total revenue [1] - Adjusted net profit grew by 31.4% year-on-year to RMB 4.54 billion, and if excluding dividends from Sinovac, the adjusted net profit still increased by 15% [1] - The company’s FY25 revenue was below expectations by 7.4% compared to the report's forecast and 3.9% compared to Bloomberg consensus, while adjusted net profit fell short by 27.5% and 9.0% respectively, mainly due to a milestone payment from Merck not being recognized as expected [1] - The company is expected to continue steady growth in FY26, driven by stable generic drug revenue and ongoing sales momentum from innovative drugs [1] Financial Summary - FY24A revenue is projected at RMB 28.87 billion, with a year-on-year growth of 10.2%, and FY25A revenue at RMB 31.83 billion, with a growth of 10.3% [2] - Adjusted net profit for FY26E is estimated at RMB 4.79 billion, reflecting a growth of 5.4% [2] - The adjusted earnings per share for FY26E is expected to be RMB 0.26, with a projected adjusted P/E ratio of 20.7 times [2] Target Price and Market Performance - The target price is set at HKD 8.70, down from the previous target of HKD 9.40, indicating a potential upside of 47.7% from the current price of HKD 5.89 [3] - The company has a market capitalization of HKD 110.5 billion and a 52-week price range of HKD 9.01 to HKD 3.34 [3] Shareholder Structure - Major shareholders include Xie Chengrun with 21.6% and Zheng Xiangling with 15.8% [4] Price Performance - The stock has shown a negative absolute return of -2.6% over the past month and -8.3% over the past three months [5]

Investment Rating - The report maintains a "Buy" rating for China Biopharmaceutical (1177 HK) [7] Core Views - The company reported a revenue growth of 10.3% year-on-year to RMB 31.83 billion for FY25, with innovative product revenue increasing by 26.2% to RMB 15.2 billion, accounting for 47.8% of total revenue [1] - Adjusted net profit grew by 31.4% year-on-year to RMB 4.54 billion, and if excluding dividends from Sinovac, the adjusted net profit still increased by 15% [1] - The company’s FY25 revenue was below expectations by 7.4% compared to the report's forecast and 3.9% compared to Bloomberg consensus, while adjusted net profit fell short by 27.5% and 9.0% respectively, mainly due to a milestone payment from Merck not being recognized as expected [1] - The company is expected to continue steady growth in FY26, driven by stable generic drug revenue and ongoing sales momentum from innovative drugs [1] Financial Summary - FY24A revenue is projected at RMB 28.87 billion, with a year-on-year growth of 10.2% - FY25A revenue is projected at RMB 31.83 billion, with a year-on-year growth of 10.3% - FY26E revenue is projected at RMB 36.13 billion, with a year-on-year growth of 13.5% [2] - Adjusted net profit for FY26E is expected to be RMB 4.79 billion, reflecting a year-on-year growth of 5.4% [2] - The adjusted earnings per share for FY26E is projected at RMB 0.26 [2] Target Price and Market Performance - The target price is set at HKD 8.70, down from the previous target of HKD 9.40, indicating a potential upside of 47.7% from the current price of HKD 5.89 [3] - The market capitalization is approximately HKD 110.5 billion [3] Shareholder Structure - The major shareholders include Xie Chengrun with 21.6% and Zheng Xiangling with 15.8% [4] Price Performance - The stock has shown a 1-month absolute return of -2.6% and a 3-month return of -8.3% [5]

Group 1 - China National Pharmaceutical Group (01177) announced that on March 27, 2026, the trustee will purchase an additional 4.65 million shares from the market [1] - The average price per share for the purchase is approximately HKD 5.8814 [1] - This transaction is conducted under the terms and conditions of the plan rules, with shares held in trust for selected participants [1]

Group 1 - The core point of the article is that China Biopharmaceutical (01177) announced a share buyback plan, intending to repurchase 5.35 million shares at a cost of HKD 31.438 million [2] Group 2 - The share buyback is scheduled to take place on March 27, 2026 [2]